Inhibrx Biosciences is trading at $84.33, up +5.51%, with sector and broader-market strength a plausible backdrop; no company-specific catalyst was identified. - On November 4, 2026, healthcare stocks were higher premarket and biotech ETF IBB was up 2.9%. - Major U.S. indexes were also rising; available company news pointed to scheduled future scientific presentations, not a new event today.